Abstract
No public abstract is available from the verified source records.
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureJaclyn Bjelac, Stacy Silvers, Brian Schroer
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Asthma & Immunology. Addressing health disparities in food allergy: a position statement of the AAAAI prior authorization task force
10.1016/j.jaci.2024.10.008 · 2025
Racial, ethnic, and socioeconomic differences in food allergies in the US
10.1001/jamanetworkopen.2023.18162 · 2023
Health disparities in pediatric food allergy
10.1016/j.anai.2022.04.022 · 2022
Feast for thought: a comprehensive review of food allergy 2021-2023
10.1016/j.jaci.2023.11.918 · 2024
Food allergy across the globe
10.1016/j.jaci.2021.10.018 · 2021
Food insecurity in children and adults with food allergies
10.1016/j.anai.2022.08.012 · 2022
The natural history of food allergy
10.1016/j.jaip.2015.11.024 · 2016
Biomarkers of diagnosis and resolution of food allergy
2020
Encouraging trends in peanut allergy prevention: real-world impact of prevention guidelines available
10.1542/peds.2025-072593 · 2025
Prevalence and characteristics of accidental ingestions among pediatric food allergy patients
10.1016/j.jaip.2024.08.006 · 2024
Mental health risks in children with food allergies: a population-based comparison of food allergies with other chronic conditions
10.1007/s00431-025-06316-0 · 2025
Mechanisms of food allergy
10.1016/j.jaci.2017.11.005 · 2018
New approaches in childhood IgE-mediated food allergy treatment
10.1097/aci.0000000000001058 · 2025
Navigating the landscape of food allergies: insights and perspectives from the AMCP market insights program
2024
Updates in food allergen immunotherapy
10.1097/mop.0000000000001272 · 2023
Cost-effectiveness of oral immunotherapy for egg allergy according to age of therapy commencement
10.1016/j.jaip.2024.12.005 · 2025
Estimation of health and economic benefits of commercial peanut immunotherapy products: a cost-effectiveness analysis
10.1001/jamanetworkopen.2019.3242 · 2019
Shared decision-making in food allergy: navigating an exciting era
2024
Viewing pediatric food oral immunotherapy through an ethical lens — a narrative systematic review
10.1016/j.jaip.2023.03.024 · 2023
Goldilocks zone: allergists’ perceptions of family anxiety and investment in food allergy oral immunotherapy
2025
Long-term outcome of peanut oral immunotherapy — real-life experience
10.1111/pai.12914 · 2018
Real-world experience with peanut oral immunotherapy: lessons learned from 270 patients
10.1016/j.jaip.2018.05.023 · 2019
Efficacy and safety of oral immunotherapy in children aged 1-3 years with peanut allergy (the immune tolerance network IMPACT trial): a randomized placebo-controlled study
10.1016/s0140-6736(21)02390-4 · 2022
Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomized, double-blind, placebo-controlled, phase 2 study
10.1016/s0140-6736(19)31793-3 · 2019
Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety
10.1016/s0140-6736(19)30420-9 · 2019
Oral immunotherapy and risk of eosinophilic esophagitis in children: 15 years’ experience
10.1097/mpg.0000000000003631 · 2023
Continuous and daily oral immunotherapy for peanut allergy: results from a 2-year open-label follow-on study
10.1016/j.jaip.2020.12.029 · 2021
Peanut oral immunotherapy using 30 mg and 300 mg maintenance doses
2025
Unresolved referenced work
2024
Allergen-specific IgE is a stronger predictor of remission following peanut oral immunotherapy than age in children aged 1-10 years
10.1111/all.16451 · 2025
Relation between eosinophilic esophagitis and oral immunotherapy for food allergy: a systematic review with meta-analysis
10.1016/j.anai.2014.08.004 · 2014
Sublingual and patch immunotherapy for food allergy
10.1016/j.iac.2019.09.008 · 2020
The use of grocery-sourced real-food solutions in sublingual immunotherapy for food allergies
10.1016/j.anai.2025.03.001 · 2025
Desensitization and remission after peanut sublingual immunotherapy in 1- to 4-year-old peanut-allergic children: a randomized, placebo-controlled trial
10.1016/j.jaci.2023.08.032 · 2024
Peanut component-specific IgE and IgG4 are modulated by sublingual immunotherapy and are associated with remission in 1-4-year-old children
2025
The safety and efficacy of sublingual and oral immunotherapy for milk allergy
10.1016/j.jaci.2011.10.023 · 2012
Phase 3 trial of epicutaneous immunotherapy in toddlers with peanut allergy
10.1056/nejmoa2212895 · 2023
Effect of epicutaneous immunotherapy vs placebo on reaction to peanut protein ingestion among children with peanut allergy: the PEPITES randomized clinical trial
10.1001/jama.2019.1113 · 2019
Intralymphatic immunotherapy for allergic rhinitis: a systematic review and meta-analysis
10.2500/aap.2021.42.210028 · 2021
Intralymphatic immunotherapy for peanut allergy: a pilot study (abstract)
10.1016/j.jaci.2018.12.780 · 2019
Racial and ethnic representation in food allergen immunotherapy trial participants: a systematic review
10.1001/jamanetworkopen.2024.32710 · doi-reference
Two-year post-treatment outcomes following peanut oral immunotherapy in the probiotic and peanut oral Immunotherapy-003 long-term (PPOIT-003LT) study
10.1111/all.16262 · doi-reference
Use of a liver-targeting nanoparticle platform to intervene in peanut-induced anaphylaxis through delivery of an Ara h2 T-cell epitope
10.1016/j.nantod.2021.101370 · doi-reference
Fecal microbiota transplantation alleviates food allergy in neonatal mice via the PD-1/PD-L1 pathway and change of the microbiota composition
10.1016/j.waojou.2024.100969 · doi-reference
Probiotic peanut oral immunotherapy versus oral immunotherapy and placebo in children with peanut allergy in Australia (PPOIT-003): a multicentre, randomised, phase 2b trial
10.1016/s2352-4642(22)00006-2 · doi-reference
A mouse model of the LEAP study reveals a role for CTLA-4 in preventing peanut allergy induced by environmental peanut exposure
10.1016/j.jaci.2022.02.024 · doi-reference
Prevention of food allergy development and suppression of established food allergy by neutralization of thymic stromal lymphopoietin, IL-25, and IL-33
10.1016/j.jaci.2017.02.046 · doi-reference
A phase II study of Bruton’s tyrosine kinase inhibition for the prevention of anaphylaxis
10.1172/jci172335 · doi-reference
Short-term ibrutinib therapy suppresses skin test responses and eliminates IgE-mediated basophil activation in adults with peanut or tree nut allergy
10.1016/j.jaci.2017.12.987 · doi-reference
Patient outcomes and safety of combination biologic therapy with dupilumab: a systematic review
10.1016/j.anai.2025.04.012 · doi-reference
Phase 2a randomized, placebo-controlled study of anti–IL-33 in peanut allergy
10.1172/jci.insight.131347 · doi-reference
Dupilumab as an adjunct to oral immunotherapy in pediatric patients with peanut allergy
10.1111/all.16420 · doi-reference
Food allergy clinical course in children and adolescents treated with dupilumab for atopic dermatitis
10.1016/j.anai.2025.07.023 · doi-reference
Efficacy and safety of dupilumab in children with peanut allergy: a multicenter, open-label, phase II study
10.1111/all.16404 · doi-reference
New evidence in food allergies treatment
10.1097/aci.0000000000000999 · doi-reference
IgE-neutralizing UB-221 mAb, distinct from omalizumab and ligelizumab, exhibits CD23-mediated IgE downregulation and relieves urticaria symptoms
10.1172/jci157765 · doi-reference
Efficacy and safety of ligelizumab in chronic spontaneous urticaria: a systematic review and meta-analysis of randomized controlled trials
10.1007/s40261-025-01436-9 · doi-reference
Omalizumab as an adjuvant in food allergen immunotherapy
10.1097/aci.0000000000000736 · doi-reference
Long-term outcome of peanut oral immunotherapy facilitated initially by omalizumab
10.1016/j.jaip.2018.09.015 · doi-reference
Introduction of allergenic foods after treatment with omalizumab
10.1016/j.jaci.2025.05.014 · doi-reference
A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients
10.1016/j.jaci.2013.09.046 · doi-reference
Therapeutic monoclonal antibodies in allergy: targeting IgE, cytokine, and alarmin pathways
10.1111/imr.13380 · doi-reference
Biologics in food allergies: emerging therapies
10.1016/j.iac.2024.07.004 · doi-reference
Omalizumab for the treatment of multiple food allergies
10.1056/nejmoa2312382 · doi-reference